Axsome Therapeutics, Inc.

Listed Company

AXSMCIK 0001579428NasdaqLarge AcceleratedPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$638.50M

Net Income

$-183.17M

Total Assets

$689.80M

Equity

$88.30M

Shares Out

51.46M

Op. Cash Flow

$-93.41M

AXSM$229.97+104.87% · past yearDBEQ Basic

Daily closing prices

Business

Axsome Therapeutics is a fully integrated biopharmaceutical company developing innovative medicines for central nervous system conditions. The company markets three FDA-approved products: AUVELITY for major depressive disorder, SUNOSI for excessive daytime sleepiness, and SYMBRAVO for acute migraine treatment. Axsome operates a commercial infrastructure in the United States and advances a pipeline of clinical-stage candidates including AXS-05 for Alzheimer's disease agitation and smoking cessation, solriamfetol for multiple neurological indications, AXS-12 for narcolepsy, AXS-14 for fibromyalgia, and AXS-17 for epilepsy, leveraging proprietary chemistry and formulation technologies.

Summary from 10-K filed 2026-02-23

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	638	386	271	50	—
Cost of revenue (excluding amortization and depreciation)	47	33	26	5	—
Research and development	183	187	98	58	58
Selling, general and administrative	571	411	323	159	67
Loss (Gain) in fair value of contingent consideration	−2	28	49	3	—
Intangible asset amortization	6	6	6	4	—
Total operating expenses	805	666	502	230	125
Loss from operations	−167	−281	−232	−180	−125
Interest expense, net	−7	−7	−6	−7	−6
Loss on debt extinguishment	−10	—	—	—	—
Loss before income taxes	−184	−287	−238	−187	−130
Income tax benefit (expense)	500,000	−85,000	−960,000	—	—
Net loss	−183	−287	−239	−187	−130
Net loss per common share, basic	−3.68	−5.99	−5.27	−4.6	−3.47
Net loss per common share, diluted	−3.68	−5.99	−5.27	−4.6	−3.47
Weighted average common shares outstanding, basic	50	48	45	41	38
Weighted average common shares outstanding, diluted	50	48	45	41	38

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	323	315	386	201	86
Accounts receivable, net	224	142	95	38	—
Inventories, net	28	16	15	4	—
Prepaid and other current assets	14	12	8	3	45,286
Total current assets	589	485	504	246	87
Equipment, net	562,000	584,000	846,000	722,000	283,846
Right-of-use asset	21	5	7	420,000	660,162
Goodwill	12	12	12	10	—
Intangible asset, net	41	47	53	60	—
Non-current inventory and other assets	27	19	11	15	322,910
Total assets	690	568	588	331	88
Accounts payable	66	72	41	39	13
Accrued expenses and other current liabilities	233	148	91	52	9
Operating lease liability, current portion	434,000	2	1	425,000	620,675
Contingent consideration, current	10	8	6	6	—
Short-term borrowings	70	0	—	—	—
Total current liabilities	379	230	139	97	23
Contingent consideration, non-current	78	92	73	31	—
Loan payable, long-term	118	181	178	94	49
Operating lease liability, long-term	23	6	7	—	—
Finance lease liability, long-term	4	3	—	—	—
Total liabilities	602	511	397	222	72
Preferred stock, $0.0001 par value per share (10,000,000 shares authorized, none issued and outstanding)	—	—	—	—	—
Common stock, $0.0001 par value per share (150,000,000 shares authorized, 50,882,766 and 48,667,587 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively)	5,000	5,000	5,000	4,000	3,782
Additional paid-in capital	1,394	1,180	1,027	706	425
Accumulated deficit	−1,306	−1,123	−836	−596	−409
Total stockholders equity	88	57	191	110	16
Total liabilities and stockholders equity	690	568	588	331	88

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−183	−287	−239	−187	−130
Stock-based compensation expense	94	85	63	38	21
Amortization of debt discount	1	3	3	1	1
Depreciation	503,000	532,000	459,000	263,000	76,000
Gain from lease modification	−2	—	—	—	—
Non-cash lease expense	3	1	1	1	1
Right-of-use asset amortization for finance lease	2	1	—	—	—
Accounts receivable, net	−82	−47	−57	−38	—
Inventories, net	−11	744,000	−8	−1	—
Prepaid expenses and other current assets	−2	−4	−5	−3	103,000
Non-current inventory and other assets	−5	−3	4	−4	−6,000
Accounts payable	−6	31	2	25	−355,000
Accrued expenses and other current liabilities	84	56	36	44	582,000
Operating lease liability	−535,000	−422,000	154,000	—	—
Net cash used in operating activities	−93	−128	−145	−117	−108
Purchases of equipment	−480,000	−270,000	−582,000	−702,000	−308,000
Net cash used in investing activities	−480,000	−270,000	−582,000	−54	−308,000
Proceeds from draw down of debt	330	—	85	45	—
Payment of debt issuance costs	−4	—	−1	−487,000	−309,000
Repayment of debt	−332	—	—	—	—
Payments on principal portion of finance lease obligation	−2	−990,000	—	—	—
Proceeds from issuance of common stock upon financing	68	41	259	244	7
Cash paid for common stock issuance costs	−1	−816,000	−16	−7	−223,000
Proceeds from issuance of common stock upon exercise of options and under employee stock purchase plan	60	31	12	6	—
Payment of contingent consideration	−10	−8	−6	−2	—
Payments of tax withholdings on stock awards	−7	−4	−2	−532,000	−176,000
Net cash provided by financing activities	101	58	331	285	11
Net increase (decrease) in cash	8	−71	185	114	−97
Interest paid	15	20	17	8	5
Operating lease right-of-use asset obtained in exchange for operating lease liability	24	—	8	561,000	—
Finance lease right-of-use asset obtained in exchange for finance lease liability	5	5	—	—	—
Decrease in operating lease right-of-use asset due to lease modification	5	—	—	—	—
Decrease in operating lease liability due to lease modification	8	—	—	—	—
Issuance of warrants in connection with debt financing	—	—	2	0	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Axsome Therapeutics, Inc.'s CIK number?

Axsome Therapeutics, Inc.'s SEC CIK number is 0001579428 (1579428). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Axsome Therapeutics, Inc.'s SEC filings?

All of Axsome Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Axsome Therapeutics, Inc. last report earnings?

Axsome Therapeutics, Inc. (AXSM) most recently filed an earnings 8-K with the SEC on May 4, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-202506). This is Axsome Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Axsome Therapeutics, Inc.'s most recent earnings 8-K?

Axsome Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 4, 2026 under accession 0001193125-26-202506. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Axsome Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →